Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects
Status:
Completed
Trial end date:
2018-08-07
Target enrollment:
Participant gender:
Summary
The aim of the study is to assess whether renal impairment could affect fevipiprant
pharmacokinetics (PK) to the extent that dosage adjustment is appropriate for this patient
population.
The study also aims to determine the effect of dialysis on the fevipiprant pharmacokinetic
profile as the procedure might remove a significant fraction of the drug.